51
Participants
Start Date
July 27, 2021
Primary Completion Date
July 24, 2023
Study Completion Date
July 24, 2023
ABP-450
ABP-450 (prabotulinumtoxinA) contains a 900kDA botulinum toxin type-A complex produced by the bacterium Clostridium botulinum.
Emory University, Atlanta
Neurology One, Winter Park
Infinity Clinical Research LLC, Hollywood
Brainstorm Research, Miami
University of South Florida, Tampa
Vanderbilt University Medical Center, Nashville
Veracity Neuroscience LLC, Memphis
The Orthopedic Foundation, New Albany
The Cleveland Clinic Foundation, Cleveland
Quest Research Institute - Hunt - PPDS, Farmington Hills
Michigan State University, East Lansing
Rush University Medical Center, Chicago
Baylor College of Medicine, Houston
Arizona Neuroscience Research, Phoenix
University of New Mexico, Albuquerque
Cleveland Clinic Lou Ruvo Center for Brain Health, Cleveland
Loma Linda University, Loma Linda
Parkinson's and Movement Disorder Institute, Fountain Valley
Neuro Pain Medical Center, Fresno
New England Institute for Neurology and Headache, Stamford
Lead Sponsor
AEON Biopharma, Inc.
INDUSTRY